Minireviews
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Methodol. Dec 26, 2015; 5(4): 223-229
Published online Dec 26, 2015. doi: 10.5662/wjm.v5.i4.223
Forkhead box protein A2 and T helper type 2-mediated pulmonary inflammation
Ling Sun, Xiao-Ju Tang, Feng-Ming Luo
Ling Sun, Xiao-Ju Tang, Laboratory of Cardiovascular Diseases Research Center of Regeneration Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Feng-Ming Luo, Department of Pulmonary Diseases, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Feng-Ming Luo, Department of Family Medicine, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China
Author contributions: Sun L and Tang XJ generated the figures and wrote the manuscript; Luo FM designed the aim of the editorial and wrote the manuscript.
Supported by The National Natural Science Foundation of China, Nos. 30871118, 30971325, 81270129 and 81470268 (FL); and grants from Department of Science and Technology of Sichuan Province, Nos. 09ZQ026-020 and 2009SZ0190 (FL).
Conflict-of-interest statement: None.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Feng-Ming Luo, MD, PhD, Department of Family Medicine, West China Hospital, Sichuan University, 37 GuoXue Xiang, Chengdu 610041, Sichuan Province, China. luofengming@hotmail.com
Telephone: +86-28-85422759 Fax: +86-28-85422788
Received: January 29, 2015
Peer-review started: January 30, 2015
First decision: March 6, 2015
Revised: March 24, 2015
Accepted: September 29, 2015
Article in press: September 30, 2015
Published online: December 26, 2015
Abstract

The transcription factor forkhead box protein A2 (FOXA2, also known as hepatocyte nuclear factor 3β or transcription factor 3β), has been found to play pivotal roles in multiple phases of mammalian life, from the early development to the organofaction, and subsequently in homeostasis and metabolism in the adult. In the embryonic development period, FOXA2 is require d for the formation of the primitive node and notochord, and its absence results in embryonic lethality. Moreover, FOXA2 plays an important role not only in lung development, but also in T helper type 2 (Th2)-mediated pulmonary inflammation and goblet cell hyperplasia. In this article, the role of FOXA2 in lung development and Th2-mediated pulmonary inflammation, as well as in goblet cell hyperplasia, is reviewed. FOXA2 deletion in airway epithelium results into Th2-mediated pulmonary inflammation and goblet cell hyperplasia in developing lung. Leukotriene pathway and signal transducers and activators of transcription 6 pathway may mediate this inflammation through recruitment and activation of denditric cell during lung developments. FOXA2 is a potential treatment target for lung diseases with Th2 inflammation and goblet cell hyperplasia, such as asthma and chronic obstructive pulmonary disease.

Keywords: Forkhead box protein A2, T helper type 2 inflammation, Pulmonary, Development, Goblet cell hyperplasia

Core tip: The transcription factor forkhead box protein A2 (FOXA2) plays pivotal roles in embryonic development and organogenesis. Conditional deletion of FOXA2 in airway epithelial cells during the early stage of lung development will result in abnormal morphology of the lung and T helper type 2-mediated pulmonary inflammation. In addition, FOXA2 regulates the goblet cell differentiation during lung development and in pulmonary diseases such as asthma and chronic obstructive pulmonary disease. FOXA2 may be a new target for the treatment of lung disease.